Inflammatory bowel disease (IBD), most commonly referring to Crohn's disease and
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …

Opinion statement Anti-tumor necrosis factor-α (anti-TNF) therapy has become a very
important modality in the treatment of patients with inflammatory bowel disease. A number of …

Crohn's disease and ulcerative colitis represent the most common forms of inflammatory
bowel disease (IBD), clinical conditions affecting the small and/or large bowel. It is well …

Infliximab is a chimeric monoclonal antibody (75% human, 25% murine) against tumor
necrosis factor-α, a cytokine with a central role in the pathogenesis of inflammatory bowel …

Background Symptom relief is the traditional treatment goal in Crohn's disease (CD). New
goals including mucosal healing and bowel preservation are now achievable with tumor …

The introduction in the mid-1990s of tumor necrosis factor (TNF) antagonists changed the
treatment of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) …

Despite all of the advances in our understanding of the pathophysiology of inflammatory
bowel disease (IBD), we still do not know its cause. Some of the most recently available data …

Infliximab, the chimeric monoclonal immunoglobulin (Ig) G1 antibody to tumor necrosis
factor (TNF) has changed our therapy of Crohn's disease. Infliximab is indicated in refractory …

Anti-tumour necrosis factor-alpha (TNF-a) agents have changed the way of treating
inflammatory bowel diseases (IBD) refractory to conventional medications (corticosteroids …

Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis
factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed …